Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP
about
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewGenetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab.ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complexSynergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphomaOverexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas.Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma.HIV-Infected Spleens Present Altered Follicular Helper T Cell (Tfh) Subsets and Skewed B Cell Maturation.CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3.hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies.Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.A mix of S and ΔS variants of STAT3 enable survival of activated B-cell-like diffuse large B-cell lymphoma cells in culture.Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human Autoimmunity.ALDH1A1 induces resistance to CHOP in diffuse large B-cell lymphoma through activation of the JAK2/STAT3 pathway.STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia.Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation.Targeting angiogenesis in renal cell carcinoma.Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.STAT3 inhibitors: finding a home in lymphoma and leukemia.STAT3 Target Genes Relevant to Human Cancers.STAT3 in Cancer-Friend or Foe?Precision therapy for lymphoma--current state and future directions.Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma.Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.Synergy of interleukin 10 and toll-like receptor 9 signalling in B cell proliferation: Implications for lymphoma pathogenesis.Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity.Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.GLI1 inhibitor GANT61 exhibits antitumor efficacy in T-cell lymphoma cells through down-regulation of p-STAT3 and SOCS3.STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expressionDCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.Prognostic factors for primary central nervous system lymphomas treated with high-dose methotrexate-based chemo-radiotherapy.Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma.B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.
P2860
Q27304386-71D607B6-4F9C-4F20-AA1D-B92CAC48296CQ33556514-B06500F3-AFF9-47D3-81F2-BABB94DAB9F4Q34016520-6073CD50-8BB2-4CAA-BCA9-F1E03B639DC3Q34104112-AB6EA576-DCE7-4645-A234-68EE0951CD9AQ34287747-43D0EED9-869B-4C52-95C3-3BC1627C15BFQ34695303-DFAB9484-93F5-4812-B6E7-92C8281FB330Q35080097-CF3AA981-4916-4295-94A0-596313E1F7F3Q35821193-68DF31A1-BD21-4EAB-AE97-E8A1C56FFC27Q36082118-C9C9AB40-A452-4730-B4C6-3158F6EE0ED8Q36298736-18C57148-4921-4B6B-8834-7BA583E7EC1DQ36413919-3477F730-49AC-4793-9759-BD4D61286733Q36507578-34C5BAFA-06F9-42AF-8186-EB96F6FE0ABFQ37146688-0FD9EA70-14C5-4E7D-B910-D2E7697B7F43Q37153681-EAC5D5C5-FB21-4C18-B8D2-65FF02448048Q37229779-90E09F75-98AE-4064-A1E3-4F8CB034D5A4Q37362593-AF635311-7DA7-4A45-9F7F-A201E41D178BQ37558207-9884BF92-0A46-4ADB-8739-68775ACA977EQ37576259-9BC78C6F-A073-4244-8B03-76B9481E5824Q38132231-DBA970F7-F997-4DE0-8C44-2D62AEAEA902Q38179500-6980EF4E-B794-4B44-90B6-523B230FBF91Q38202556-2114D8FB-F8B6-4138-81E6-DD9359131C86Q38205362-C515B23C-E141-457A-A370-B93586967CF7Q38226313-FC303696-50C5-4CBC-AC1B-3989337317D3Q38241102-0FC9FB40-B5BD-4A39-A645-90A5C7289680Q38376847-FC5F59BF-E43F-43F9-8CB7-2947AF842BB7Q38686915-2BC6BB87-F400-4C5D-B9CC-9293D4E48228Q38741291-25086A91-3F65-4F50-8560-BDB61B4E44E3Q38743752-ED52723C-203E-440D-ADD4-125FE1235C71Q38819065-102CCE25-BB8D-4C45-8F03-553566F96035Q38945255-11B1011C-C1A5-4292-9B31-125C12391211Q38990306-D044E2A6-BF98-4C2E-A60A-FB662DEC987BQ39016086-0BF0E6CC-0C76-4CE8-BB46-9E3438147D10Q39974818-4DE81077-6428-4AA9-A44C-19066EE0AD2CQ41472066-016E5356-14BE-4917-BC0F-1336E227F71CQ41573983-6F5B1001-6DA2-41D6-81F3-CF3A0351B607Q45914413-BF2A4364-8D4E-4DB1-8413-5B76F72FDFABQ47692328-728BDE89-6B2E-4565-BF6B-BDE96CC4512BQ49358927-6B44B451-E424-42A9-AC9D-C8D2FF9D26FAQ49872904-B0266DA6-E8C8-46B7-9840-195511E74C9FQ50056654-27EEF9AA-1558-45D6-A00B-0B288ADD27AD
P2860
Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Activation of the STAT3 signal ...... l lymphoma treated with R-CHOP
@en
Activation of the STAT3 signal ...... lymphoma treated with R-CHOP.
@nl
type
label
Activation of the STAT3 signal ...... l lymphoma treated with R-CHOP
@en
Activation of the STAT3 signal ...... lymphoma treated with R-CHOP.
@nl
prefLabel
Activation of the STAT3 signal ...... l lymphoma treated with R-CHOP
@en
Activation of the STAT3 signal ...... lymphoma treated with R-CHOP.
@nl
P2093
P2860
P50
P356
P1476
Activation of the STAT3 signal ...... l lymphoma treated with R-CHOP
@en
P2093
Anamarija M Perry
Andreas Rosenwald
B Belinda Ding
B Hilda Ye
Chengfeng Bi
Chunsun Jiang
Dennis D Weisenburger
German Ott
James R Cook
P2860
P304
P356
10.1200/JCO.2012.45.6004
P407
P50
P577
2013-11-12T00:00:00Z